Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,465,178

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

by Zacks Equity Research

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Humana (HUM) Taps Debt Market With Senior Note Pricing

by Zacks Equity Research

Humana (HUM) exhibits monetary discretion by pricing senior secured notes to procure funds.

    Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails

    by Zacks Equity Research

    Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.

    McKesson (MCK) Is Up 6.34% in One Week: What You Should Know

    by Zacks Equity Research

    Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Here's Why You Should Retain Edwards Lifesciences (EW) Now

    by Zacks Equity Research

    Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

    Myriad Genetics (MYGN) Makes Progress in Precision Oncology

    by Zacks Equity Research

    Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

    Here's Why You Should Hold on to Cerner (CERN) Stock Now

    by Zacks Equity Research

    Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

    Here's Why You Should Retain Abbott (ABT) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.

    Walgreens (WBA), Village MD Plan to Expand Into New Hampshire

    by Zacks Equity Research

    Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.

    Here's Why You Should Hold on to Alcon (ALC) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

    Align Technology (ALGN) Debuts Latest Feature for ClinCheck

    by Zacks Equity Research

    Align Technology's (ALGN) CBCT integration feature for ClinCheck will enable doctors to treat a broader range of cases with the Invisalign clear aligners.

    Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

    by Zacks Equity Research

    Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

    Here's Why You Should Hold on to Insulet (PODD) Stock For Now

    by Zacks Equity Research

    Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.

    Here's Why You Should Buy McKesson (MCK) Stock Right Now

    by Zacks Equity Research

    McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

    Here's Why You Should Retain ResMed (RMD) Stock for Now

    by Zacks Equity Research

    ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

    Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for FXG

    Here's Why You Should Hold on to DaVita (DVA) Stock Now

    by Zacks Equity Research

    DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.

    Here's Why You Should Hold on to Integra (IART) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.

    Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise

    by Zacks Equity Research

    Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

    Boston Scientific (BSX) Hurt by Price and Volume Issues

    by Zacks Equity Research

    The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.

    Here's Why You Should Retain Cardinal Health (CAH) Stock Now

    by Zacks Equity Research

    Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

    DexCom (DXCM) to Boost Diabetes Management With New Approval

    by Zacks Equity Research

    DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.

    Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now

    by Zacks Equity Research

    Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.

    Here's Why You Should Hold on to Medtronic (MDT) Stock For Now

    by Zacks Equity Research

    Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.

    McKesson (MCK) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, McKesson (MCK) closed at $284.85, marking a +1.29% move from the previous day.